伴同性動物疫苗市場報告：2030 年趨勢、預測與競爭分析

伴同性動物疫苗趨勢和預測

預計到 2030 年，全球伴同性動物疫苗市場將達到 48 億美元，2024 年至 2030 年複合年成長率為 6.3%。該市場的主要促進因素是人們對寵物疫苗接種重要性的認知不斷提高、通用感染疾病病例不斷增加以及世界各地對養寵物的興趣日益濃厚。全球伴同性動物疫苗市場的未來看起來充滿希望，醫院/診所和研究實驗室市場存在機會。

Lucintel 預測，由於飼主對疫苗接種以保護寵物免受嚴重疾病的重要性的認知不斷提高，狗仍將是最大的細分市場。

在這個市場中，醫院和診所預計將在預測期內實現最高成長。由於寵物擁有量較高以及該地區人們對寵物疫苗接種重要性的認知不斷增強，北美仍將是最大的地區。

伴同性動物疫苗市場的新趨勢

由於技術進步、消費者偏好的變化和新的法規環境，伴同性動物疫苗市場正在快速發展。未來的趨勢正在塑造這個市場，推動疫苗開發、分銷和管理方面的創新。

• 個人化疫苗：基因分析可以開發出適合個別寵物需求的個人化疫苗，而這個概念正變得越來越流行。這種趨勢在日本和美國等國家尤其明顯，這些國家的寵物飼主正在為他們的動物尋求量身定做的醫療保健解決方案。這些疫苗非常有效且副作用最小，使其成為首選。
• 基於 DNA 和 RNA 的疫苗：DNA 和 RNA 作為疫苗的使用正在增加，因為它們可以針對多種疾病提供快速保護。此類疫苗在對抗新出現的感染疾病特別有效。許多公司正在美國和歐洲市場開發這些尖端疫苗。
• 越來越關注通用感染疾病的預防：隨著通用感染疾病變得越來越普遍，人們越來越關注疫苗，它不僅可以保護寵物免受感染疾病，還可以降低將其傳播給人類的風險。在德國等國家，這種趨勢正在加劇，動物健康是公共衛生的重要組成部分。此類疫苗將在綜合健康策略中發揮核心作用。
• 擴大疫苗的取得範圍：全球改善疫苗取得的勢頭不斷增強，特別是在印度和中國等新興國家。這將透過提高疫苗接種率以及透過產業和政府之間的合作使疫苗變得負擔得起並廣泛提供來改善整體動物健康結果。
• 生物技術的整合：將先進的生物技術融入疫苗開發中正在顯著改變市場。科學家開始使用 CRISPR 和合成生物學等技術來創造更安全、更好的疫苗。這一趨勢預計將導致新一代疫苗具有更高的功效、在設計過程中滿足安全需求以及快速且有效率的生產。

伴同性動物疫苗市場的未來正受到這些向更有效率、個人化和可及的疫苗發展的趨勢的推動。這些進展將重塑疫苗的配製、傳播和使用方式，從而改善全球伴同性動物的健康前景。

伴同性動物疫苗市場的最新趨勢

幾項重大發展推動了伴同性動物疫苗市場的成長和演變。這些改進顯示對新型高效疫苗的需求不斷增加，以及最大限度地提高全球可及性和有效性的努力。

• 創新的 DNA 疫苗：DNA 疫苗的最新進展正在以更少的劑量實現更大的覆蓋範圍。這些疫苗旨在對抗多種疾病，為寵物動物提供更有效、更有針對性的疫苗接種選擇。
• 擴大全球生產：疫苗製造商正在投資建造新的生產工廠，以增加疫苗供應，特別是在中國和印度等開發中國家。這種擴張對於滿足世界各地對疫苗不斷成長的需求並確保按時供應至關重要。
• 預防通用感染疾病的聯合計畫：獸醫研究中心和製藥公司之間的聯合計畫正在開發針對通用傳染病的疫苗。這些疫苗可以保護寵物和人類，反映出人們對公共衛生方法的日益關注。
• 低成本免疫計劃：一些公司正在推出廉價疫苗以提高免疫率，特別是在開發中國家。這些市場舉措得到了公共衛生計劃的支持，其主要目標是讓公眾意識到寵物疫苗接種的重要性並減少該市場的健康風險。
• 個人化疫苗的製造：在日本和其他已開發市場，個人疫苗已成為一種偏好，對品種和個人疫苗的研究正在取得進展。這是因為它更有效並且被飼主所接受，因為它滿足了寵物的特定醫療保健需求。

這些全球趨勢透過培育創新理念、獲得全球關注以及提高疫苗的整體效率和可用性，正在塑造伴同性動物疫苗市場。展望未來，這將對改善伴同性動物醫療保健服務的未來潛在需求產生影響。

伴同性動物疫苗市場的策略性成長機會

伴同性動物疫苗市場提供了幾個策略性成長機會，特別是在某些關鍵應用領域。這些源自於疫苗技術的進步、寵物擁有量的增加以及對全球動物健康日益成長的興趣。

• 疾病特異性疫苗：針對特定地區流行的特定疾病的疫苗的開發代表了一個主要的成長機會。透過專注於生產高流行性疾病疫苗，公司可以提供自訂的解決方案，成功應對當地的健康挑戰。
• 生物技術主導的疫苗開發：將 CRISPR 和合成生物學等生物技術納入疫苗開發中，正在開闢生產更有效、更安全疫苗的新方法。在這個領域，公司有潛力透過提供尖端疫苗來滿足寵物飼主不斷變化的需求，從而進行創新並獲得市場佔有率。
• 新興市場的擴張：寵物飼主數量的不斷增加以及對優質獸醫服務的需求不斷成長，使得印度和中國等新興市場成為有吸引力的投資目的地。在這些市場建立本地生產設施和分銷網路的公司擁有很高的成長機會。
• 線上和直接面對消費者的銷售：線上平台和直接面對消費者的管道的興起正在為疫苗分銷創造新的機會。利用電子商務和數位行銷的公司可以為更多人提供疫苗，特別是在獸醫服務有限的地區。
• 預防性醫療保健計劃：包括疫苗、定期檢查和其他基本服務在內的預防性醫療保健計劃正在增加。這些套餐使寵物飼主更容易接受疫苗接種等常規醫療護理，最終改善所有動物的健康。

技術創新、市場擴張和疫苗供應等策略性成長機會已經改變了伴同性動物疫苗市場。透過利用這些機會，公司可以在這個不斷變化的行業中獲得優勢。

伴同性動物疫苗市場促進因素與挑戰

影響伴同性動物疫苗市場的關鍵促進因素包括技術創新、寵物擁有量的增加以及動物健康意識的提高。但障礙也存在，包括監管合規障礙、高昂的研發成本以及一些飼主對疫苗的猶豫。這些因素共同影響市場的狀況。

推動伴同性動物疫苗市場的因素包括：

1.技術創新：生物技術的進步，例如基於DNA和RNA的疫苗，正在導致更有效的標靶疫苗的生產，從而改善寵物的健康並擴大馬蘇的市場規模。

2. 增加寵物擁有量：寵物擁有量的增加，特別是在都市區，增加了對伴同性動物疫苗的需求，以確保寵物的醫療保健。

3.提高動物健康意識：疫苗接種率很高，特別是在醫學素養率較高的新興市場，因為人們對疫苗接種預防疾病的知識很豐富。

4. 政府支持和監管：政府支持政策和簡化的監管流程正在促進新興市場的疫苗開發和分配。

5.通用感染疾病的增加：通用感染疾病的日益流行增加了對同時針對動物和人類的疫苗的需求。

伴同性動物疫苗市場面臨的挑戰包括：

1. 監管障礙：這項挑戰可能會限制疫苗公司，因為應對複雜且地區不同的法規環境可能會延遲疫苗核准和市場准入。

2.研發成本高：研發成本高：研發成本高，特別是創新疫苗，會阻礙市場進入並抑制中小企業的競爭。

3. 疫苗猶豫不決：安全問題、副作用和錯誤訊息阻礙了一些飼主為寵物接種疫苗，從而阻礙了市場成長。

這些促進因素和挑戰決定了伴同性動物疫苗市場將如何發展。儘管存在許多與技術進步和需求增加相關的機會，但克服監管的財務障礙將是該行業持續成長的關鍵。

伴同性動物疫苗按市場

該研究包括按產品類型、物種類型、最終用途和地區分類的伴同性動物疫苗的全球預測。

國家伴同性動物疫苗市場前景

由於寵物數量的增加、疫苗技術的創新以及動物健康意識的提高，全球伴同性動物疫苗市場正在經歷一些改善。此外，政府舉措以及對可保護寵物免受各種疾病的安全有效疫苗的需求不斷增加，也促進了該市場的成長。以下的摘要重點介紹了美國、中國、德國、印度和日本的最新發展。

• 美國：在美國，基於 DNA 的伴同性動物疫苗的開發正在取得重大進展。這些公司正在投資研究，開發以更少劑量提供廣泛保護的疫苗。我們也致力於改善我們的分銷網路，以確保在全國範圍內及時供貨。
• 中國 在中國，中國政府正在加強對本土疫苗生產的支持。最近的發展包括與全球公司建立合作夥伴關係以及建立新的製造工廠，以提高未來疫苗的品質和可用性。也重點關注擴大都市區伴同性動物的疫苗接種覆蓋範圍。
• 德國 德國正致力於開發針對新出現的通用感染疾病的疫苗。獸醫研究機構和製藥公司最近的合作旨在開發不僅能保護動物，還能降低疾病傳播給人類的風險的疫苗。
• 印度都市區寵物擁有量的增加是印度伴同性動物疫苗市場成長的主要驅動力。最近的努力包括推出負擔得起的疫苗選擇和進行宣傳宣傳活動以提高疫苗接種率。政府也正在簡化監管核准，以更快提供新疫苗。
• 日本 在日本，有一種趨勢是為伴同性動物提供個人化疫苗，並專注於特定品種的健康問題。在這方面，最新的發展涉及先進的生物技術，可以根據個別寵物的基因譜開發客製化的疫苗，確保更好的疾病預防。

常問問題

Q.1伴同性動物疫苗的市場規模有多大？

A1. 到 2030 年，全球伴同性動物疫苗市場預計將達到 48 億美元。

Q.2伴同性動物疫苗市場的成長預測如何？

A2. 2024年至2030年，全球伴同性動物疫苗市場預計將以6.3%的複合年成長率成長。

Q.3 影響伴同性動物疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要促進因素是人們對寵物疫苗接種重要性的認知不斷提高、通用感染疾病病例不斷增加以及世界各地對養寵物的興趣日益濃厚。

Q4.市場的主要細分市場是：

A4.伴同性動物疫苗市場的前景在醫院/診所市場和研究所市場似乎很有前景。

Q5.市場的主要企業是：

A5.伴同性動物疫苗主要企業如下：

• Elanco
• Boehringer Ingelheim International
• Intervet
• Zoetis Services
• Bioveta
• Sanofi
• Bayer
• Heska
• Virbac
• Hester Biosciences

Q6.伴同性動物疫苗未來哪個區隔市場將成為最大？

A6.Lucintel 預測，由於狗飼主對疫苗接種以保護寵物免受嚴重疾病的重要性的認知不斷提高，狗將繼續成為最大的細分市場。

Q7. 未來五年哪個地區預計將成為伴同性動物疫苗市場最大的地區？

A7. 由於寵物擁有率高以及該地區人口對寵物疫苗接種重要性的認知不斷提高，北美將繼續成為最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球伴同性動物疫苗市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球寵物動物疫苗市場趨勢（2018-2023）與預測（2024-2030）
• 按產品類型分類的全球伴同性動物疫苗市場
  • 腐爛活著
  • 共軛
  • 惰性
  • 次單元
  • 類毒素
  • DNA
  • 重組
• 全球伴同性動物疫苗市場、類型
  • 狗
  • 鳥類
  • 貓科動物
  • 馬
• 全球伴同性動物疫苗市場（依最終用途）
  • 醫院/診所
  • 研究所
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 全球伴同性動物疫苗市場區域分佈
• 北美伴同性動物疫苗市場
• 歐洲伴同性動物疫苗市場
• 亞太地區伴同性動物疫苗市場
• 其他區域伴同性動物疫苗市場

第5章 競爭分析

• 產品系列分析
• 業務整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按產品類型分類的全球伴同性動物疫苗市場成長機會
  • 全球伴同性動物疫苗市場按類型分類的成長機會
  • 按最終用途分類的全球伴同性動物疫苗市場的成長機會
  • 全球伴同性動物疫苗市場成長機會（按地區）
• 全球伴同性動物疫苗市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球伴同性動物疫苗市場產能擴張
  • 全球伴同性動物疫苗市場的併購和合資企業
  • 認證和許可

第7章主要企業概況

• Elanco
• Boehringer Ingelheim International
  • Intervet
• Zoetis Services
• Bioveta
• Sanofi
• Bayer
• Heska
• Virbac
• Hester Biosciences

Companion Animal Vaccine Trends and Forecast

The future of the global companion animal vaccine market looks promising with opportunities in the hospital & clinic and research institute markets. The global companion animal vaccine market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are rising awareness about importance of pet vaccination, growing cases of zoonotic diseases, and increasing interest for pet ownership in the world.

Lucintel forecasts that canines will remain the largest segment due to increasing awareness of the importance of this vaccination among dog owners for protecting their pets from serious diseases.

Within this market, hospital & clinics are expected to witness the highest growth over the forecast period. North America will remain the largest region due to high pet ownership rates and increasing awareness of the importance of pet vaccination among the population in the region.

Emerging Trends in the Companion Animal Vaccine Market

The market for Companion Animal Vaccines is evolving at a rapid pace due to technological advances, changing consumer preferences, and new regulatory environments. Future trends are shaping up this market which prompt innovations in vaccine development, distribution, and administration.

• Personalized Vaccines: Genetic profiling has enabled the development of personalized vaccines tailored to individual pets' requirements which is making this concept increasingly popular. This trend is particularly pronounced in countries like Japan and the USA where pet owners seek bespoke healthcare solutions for their animals. These vaccines offer increased efficacy with minimum side effects hence becoming the preferred choice.
• DNA and RNA-Based Vaccines: The use of DNA and RNA as vaccines is increasing because they offer quick protection against a broad range of diseases. These kinds of vaccines are especially beneficial in fighting emerging infectious diseases. Many companies are developing these cutting-edge vaccines in the US and European markets.
• Increasing Focus on Zoonotic Disease Prevention: The emphasis on vaccines, which are not only designed to protect pets from infectious diseases but also reduce the risk of transmitting them to humans, is rising as zoonoses become more prevalent. In places like Germany where animal health is an integral part of public health, this trend is picking up. These vaccines would also be central to integrated health strategies.
• Expanding Vaccine Accessibility: There is a growing momentum towards improving vaccine access globally, particularly in emerging economies such as India and China. This has increased vaccination rates and improved overall animal health outcomes by making vaccines affordable and widely available through collaborations between businesses and governments.
• Biotechnology Integration: Incorporating advanced biotechnology into vaccine development is transforming the market. Scientists have started using technologies such as CRISPR and synthetic biology that create better yet safer vaccines. New generations of vaccines with greater effectiveness, safety needs addressed during their design process, and quick efficient production are expected to result from this trend.

The future of the companion animal vaccine market is being pushed by these trends towards more efficient, individualized, and accessible vaccines. These developments will reshape how vaccines are formulated, spread out, and put into use as a result of improving companion animals' health outlooks globally.

Recent Developments in the Companion Animal Vaccine Market

The growth and evolution of the companion animal vaccine market have been driven by several important developments. These improvements indicate an increasing need for new and efficient vaccines as well as the attempts to maximize global access and efficacy.

• Innovative DNA-based Vaccines: Recent advances in DNA-based vaccines are making great strides toward broader coverages with reduced doses. Designed to fight various diseases, these vaccines offer more effective and targeted immunization options for pet animals.
• Global Manufacturing Expansion: Vaccine producers are investing in new production plants, especially in developing countries including China and India that help increase the supply of vaccines. The expansion is crucial in addressing the increasing demand for vaccines worldwide as well as ensuring their availability on time.
• Collaborations for Zoonotic Disease Prevention: Joint ventures between veterinary research centers and pharmaceutical firms have resulted in the development of vaccines against zoonotic diseases. These vaccines serve to protect both pets and humans, which reflects a growing focus on connected public health approaches.
• Low-Cost Immunization Plan: Some corporations are introducing cheap vaccines to improve immunization rates, especially in the developing world. These market initiatives are backed up by public health programs whose main objective is to sensitize the public to the importance of pet vaccination hence reducing this market's health risks.
• Individualised Vaccine Production: In Japan and other highly-developed markets personal vaccines have become preferable, leading to research on breed or individually tailored vaccine versions. This is because they are more effective and meet the distinct healthcare needs of pets, thus being embraced by pet owners.

These trends combine to shape the companion animal vaccine market by fostering innovative ideas, extending prominence globally, and increasing vaccines' overall efficiency along with availability. Henceforth, this will influence what will occur concretely in terms of future potential demand for companion animal healthcare services as far as its improvement is concerned.

Strategic Growth Opportunities for Companion Animal Vaccine Market

Several strategic growth opportunities are available in the companion animal vaccine market, especially in certain key application segments. These arise from advancements in vaccine technology, increased pet ownership, and a growing global animal health focus.

• Disease-Specific Vaccines: The development of vaccines targeting specific diseases characterized by their prevalence in particular geographical areas represents a significant opportunity for growth. Companies can concentrate on making vaccines for diseases that are hyper-endemic, thereby providing custom-made solutions that successfully address local health challenges.
• Biotechnology-Driven Vaccine Development: The incorporation of biotechnology into vaccine development such as CRISPR and synthetic biology is opening up new ways to produce more effective and safer vaccines. In this area, companies have the potential to innovate and gain market share by providing cutting-edge vaccines that meet the changing demands of pet owners.
• Expansion in Emerging Markets: Growing numbers of pets' owners coupled with rising demand for quality veterinary services make emerging markets like India and China attractive for investment. Those companies that establish local production facilities and distribution networks within these markets will have access to the high-growth opportunities they offer.
• Online and Direct-to-Consumer Sales: The rise of online platforms and direct-to-consumer sales channels is creating new opportunities for vaccine distribution. Companies that leverage e-commerce and digital marketing can reach a wider audience, especially in places where veterinary services are limited.
• Preventive Healthcare Packages: Preventive healthcare package options that include vaccines, routine check-ups, and other basic services are on the rise. These packages make it easier for pet owners to get the medical care they need on a regular basis including vaccination among others which will eventually lead to better health for all animals.

Strategic growth opportunities like innovation, market expansion, accessibility of vaccines have changed the marketplace for Companion Animal Vaccines. Taking advantage of these opportunities will put businesses at an advantageous position in this changing industry.

Companion Animal Vaccine Market Driver and Challenges

Key drivers that shape the companion animal vaccine market include; Technological innovation, increased pet ownership, and an increase in awareness of animal health. However, there are also hurdles such as regulatory compliance barriers, high research and development costs, and some pet owners who show hesitance towards vaccines. Taken together, these elements affect what happens in the marketplace.

The factors responsible for driving the companion animal vaccine market include:

1. Technological Innovation: Biotechnology advances such as DNA and RNA-based vaccines have led to the production of more efficient targeted vaccines resulting in improved health outcomes for pets thereby expanding the market reach.

2. Increasing Pet Ownership: The higher incidence of pet ownership particularly in cities is driving up demand for companion animal vaccines so that they can ensure their pets' well-being is taken care of.

3. Growing Awareness of Animal Health: Informed people have a better vaccination rate due to their knowledge about diseases prevention by vaccination especially among developed markets where healthcare literacy levels are high among other reasons.

4. Government Support and Regulations: In emerging markets, vaccines are being developed and distributed with the help of supportive government policies and simplified regulatory processes.

5. Rise of Zoonotic Diseases: The increasing prevalence of zoonotic diseases has resulted in a demand for vaccines that address both animals and humans simultaneously.

Challenges in the companion animal vaccine market are:

1. Regulatory Hurdles: Navigating complex and varying regulatory environments across different regions can delay vaccine approvals and market entry; this challenge may limit vaccine companies.

2. High R&D Costs: High R&D costs, especially for innovative vaccines, can hinder entry into a market and curtail competition from smaller firms.

3. Vaccine Hesitancy: Safety concerns, side effects, or false information prevent some pet owners from vaccinating their pets thus hindering market growth.

These drivers along with the challenges delineate how the companion animal vaccine market is evolving. There are numerous opportunities associated with technology advancements as well as increasing demand but overcoming economic barriers to regulation will be key if this industry is to continue experiencing growth.

List of Companion Animal Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies companion animal vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the companion animal vaccine companies profiled in this report include-

• Elanco
• Boehringer Ingelheim International
• Intervet
• Zoetis Services
• Bioveta
• Sanofi
• Bayer
• Heska
• Virbac
• Hester Biosciences

Companion Animal Vaccine by Segment

The study includes a forecast for the global companion animal vaccine by product type, species type, end use, and region.

Companion Animal Vaccine Market by Product Type [Analysis by Value from 2018 to 2030]:

• Attenuated Live
• Conjugate
• Inactivated
• Subunit
• Toxoid
• DNA
• Recombinant

Companion Animal Vaccine Market by Species Type [Analysis by Value from 2018 to 2030]:

• Canine
• Avian
• Feline
• Equine

Companion Animal Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Research Institutes
• Others

Companion Animal Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Companion Animal Vaccine Market

The companion animal vaccine market has seen several improvements across the world due to increased pet ownership, innovation in vaccine technology, and growing consciousness of animal health. Moreover, this market's growth is augmented by government initiatives and a rise in demand for safe and efficient vaccines that can protect pets from different ailments. The summary below highlights recent trends within the United States, China, Germany, India, and Japan.

• United States: In America, there have been significant strides in developing DNA-based vaccines for pets. These companies are investing in research that aims at creating vaccines that offer wider protection with a lower number of doses. Moreover, efforts have been made to improve the distribution network to make them available on time across the country.
• China: In China, there has been greater support from the Chinese government toward their local vaccine production. Some of these recent developments include the establishment of new manufacturing plants together with partnerships with worldwide companies aimed at improving the quality as well as accessibility of vaccines in the future. There is also a focus on expanding vaccination coverage to companion animals living in urban areas.
• Germany: Germany has concentrated on developing vaccines against emerging zoonotic infections. Some recent collaborations between veterinary research institutes and pharmaceutical companies aim to create vaccines that not only protect animals but also reduce the risk of disease transmission to humans.
• India: The rise in urban pet ownership has been the key driver for growth in India's companion animal vaccine market. Some recent initiatives include affordable vaccine options being launched and awareness campaigns executed to increase vaccination rates. The government has also streamlined regulatory approvals to make new vaccines available more quickly.
• Japan: There is a trend towards personalized vaccines for companion animals, with an emphasis on breed-specific health issues in Japan. In this regard, some of the latest developments involve advanced biotechnology that allows for the development of custom-made immunizations based on genetic profiles of individual pets and ensures better disease prevention.

Features of the Global Companion Animal Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Companion animal vaccine market size by product type, species type, end use, and region in terms of value ($B).

Regional Analysis: Companion animal vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, species types, end uses, and regions for the companion animal vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the companion animal vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the companion animal vaccine market size?

Answer: The global companion animal vaccine market is expected to reach an estimated $4.8 billion by 2030.

Q.2 What is the growth forecast for the companion animal vaccine market?

Answer: The global companion animal vaccine market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the companion animal vaccine market?

Answer: The major drivers for this market are rising awareness about the importance of pet vaccination, growing cases of zoonotic diseases, and increasing interest for pet ownership in the world.

Q4. What are the major segments for companion animal vaccine market?

Answer: The future of the companion animal vaccine market looks promising with opportunities in the hospital & clinic and research institute markets.

Q5. Who are the key companion animal vaccine market companies?

Answer: Some of the key companion animal vaccine companies are as follows:

• Elanco
• Boehringer Ingelheim International
• Intervet
• Zoetis Services
• Bioveta
• Sanofi
• Bayer
• Heska
• Virbac
• Hester Biosciences

Q6. Which companion animal vaccine market segment will be the largest in the future?

Answer: Lucintel forecasts that canine will remain the largest segment due to increasing awareness of the importance of this vaccination among dog owners for protecting their pets from serious diseases.

Q7. In the companion animal vaccine market, which region is expected to be the largest in the next 5 years?

Answer: North America will remain the largest region due to high pet ownership rates and increasing awareness of the importance of pet vaccination among the population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the companion animal vaccine market by product type (attenuated live, conjugate, inactivated, subunit, toxoid, DNA, and recombinant), species type (canine, avian, feline, and equine), end use (hospitals & clinics, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Companion Animal Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Companion Animal Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Companion Animal Vaccine Market by Product Type
  • 3.3.1: Attenuated Live
  • 3.3.2: Conjugate
  • 3.3.3: Inactivated
  • 3.3.4: Subunit
  • 3.3.5: Toxoid
  • 3.3.6: DNA
  • 3.3.7: Recombinant
• 3.4: Global Companion Animal Vaccine Market by Species Type
  • 3.4.1: Canine
  • 3.4.2: Avian
  • 3.4.3: Feline
  • 3.4.4: Equine
• 3.5: Global Companion Animal Vaccine Market by End Use
  • 3.5.1: Hospitals & Clinics
  • 3.5.2: Research Institutes
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Companion Animal Vaccine Market by Region
• 4.2: North American Companion Animal Vaccine Market
  • 4.2.1: North American Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
  • 4.2.2: North American Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
• 4.3: European Companion Animal Vaccine Market
  • 4.3.1: European Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
  • 4.3.2: European Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
• 4.4: APAC Companion Animal Vaccine Market
  • 4.4.1: APAC Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
  • 4.4.2: APAC Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
• 4.5: ROW Companion Animal Vaccine Market
  • 4.5.1: ROW Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
  • 4.5.2: ROW Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Companion Animal Vaccine Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Companion Animal Vaccine Market by Species Type
  • 6.1.3: Growth Opportunities for the Global Companion Animal Vaccine Market by End Use
  • 6.1.4: Growth Opportunities for the Global Companion Animal Vaccine Market by Region
• 6.2: Emerging Trends in the Global Companion Animal Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Companion Animal Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Companion Animal Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Elanco
• 7.2: Boehringer Ingelheim International
  • 7.1.1: Intervet
• 7.4: Zoetis Services
• 7.5: Bioveta
• 7.6: Sanofi
• 7.7: Bayer
• 7.8: Heska
• 7.9: Virbac
• 7.10: Hester Biosciences